ZIP, I didn't include NCE because it has become somewhat irrelevant in my opinion. Patents protect it well. Has more of psychological than practical value. If we get it fine, if not I'm not concerned. Regarding being too conservative about B.O. price, I certainly hope that I am wrong there and am far too low. However, I opined conservative numbers to be on the safe side. zbd
There is no interim analysis of R-IT, at least not one written into the trial design. The only way I think we get early results is if things go so well and are so obvious that the study is halted early.
Market Data 
Markets 
AI
